Choose the brand aligned with your industry so we can best serve your needs.
For researchers, scientists, and technical professionals: Your one-stop shop for the complete range of laboratory, production, and safety products and services.
Cocktails, tablets, capsules, and individual purified formulations of protease inhibitors and phosphatase inhibitors designed to protect proteins from degradation during cell lysis and extraction.
The PI 3-K inhibitor IX, PIK-90, also referenced under CAS 677338-12-4, controls the biological activity of PI 3-K. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
The PIM1 Inhibitor II, also referenced under CAS 491871-58-0, controls the biological activity of PIM1. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
The VEGFR Tyrosine Kinase Inhibitor IV, also referenced under CAS 475108-18-0, controls the biological activity of VEGFR Tyrosine Kinase. This small molecule/inhibitor is primarily used for Phosphorylation and Dephosphorylation applications.
The Tpl2 Kinase Inhibitor II, also referenced under CAS 1186649-59-1, controls the biological activity of Tpl2 Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
The Dopamine Receptor Antagonist II, Thioridazine, HCl, also referenced under CAS 130-61-0, controls the biological activity of Dopamine Receptor. This small molecule/inhibitor is primarily used for Biochemicals applications.
The COX-2 Inhibitor III, also referenced under CAS 1177728-24-3, controls the biological activity of COX-2. This small molecule/inhibitor is primarily used for Cell Signaling applications.
A cell-permeable quinoline-sulfonamide that acts as a potent allosteric PKM2 activator both in cell-free enzymatic assays (AC50 = 17nM with 40 ng PKM2/200μL) and in cultures (AC50 = 45nM in A549 cells) via a high affinity, 2:1 stoichiometric binding, effectively locking PKM2 in an active tetrameric state resistant to known intracellular negative regulators of FBP-activated PKM2 te